KR20150030752A - 디클로페낙 제형 - Google Patents

디클로페낙 제형 Download PDF

Info

Publication number
KR20150030752A
KR20150030752A KR20157003028A KR20157003028A KR20150030752A KR 20150030752 A KR20150030752 A KR 20150030752A KR 20157003028 A KR20157003028 A KR 20157003028A KR 20157003028 A KR20157003028 A KR 20157003028A KR 20150030752 A KR20150030752 A KR 20150030752A
Authority
KR
South Korea
Prior art keywords
formulation
transdermal
present
amount
diclofenac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR20157003028A
Other languages
English (en)
Korean (ko)
Inventor
아르노 그르니에
다리오 엔. 카라라
Original Assignee
훼링 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훼링 비.브이. filed Critical 훼링 비.브이.
Publication of KR20150030752A publication Critical patent/KR20150030752A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
KR20157003028A 2012-07-12 2013-07-04 디클로페낙 제형 Withdrawn KR20150030752A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12176115 2012-07-12
EP12176115.9 2012-07-12
PCT/EP2013/064123 WO2014009241A1 (en) 2012-07-12 2013-07-04 Diclofenac formulations

Publications (1)

Publication Number Publication Date
KR20150030752A true KR20150030752A (ko) 2015-03-20

Family

ID=48741196

Family Applications (1)

Application Number Title Priority Date Filing Date
KR20157003028A Withdrawn KR20150030752A (ko) 2012-07-12 2013-07-04 디클로페낙 제형

Country Status (14)

Country Link
US (2) US9999590B2 (enExample)
EP (2) EP2872177B1 (enExample)
JP (2) JP6259454B2 (enExample)
KR (1) KR20150030752A (enExample)
CN (1) CN104428003B (enExample)
AU (1) AU2013289403B2 (enExample)
BR (1) BR112015000329A2 (enExample)
CA (1) CA2878784A1 (enExample)
HK (1) HK1204973A1 (enExample)
IL (1) IL236304A0 (enExample)
MX (1) MX2015000541A (enExample)
NZ (1) NZ702967A (enExample)
RU (1) RU2014152445A (enExample)
WO (1) WO2014009241A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164192A1 (ko) * 2018-02-22 2019-08-29 동아제약 주식회사 비스테로이드성 소염진통 활성성분을 함유하는 필름 형성 약제학적 조성물

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10813897B2 (en) * 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
BR112015000329A2 (pt) * 2012-07-12 2017-06-27 Ferring Bv formulações de diclofenac
US9855234B2 (en) * 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
ES2893527T3 (es) 2016-12-28 2022-02-09 Hisamitsu Pharmaceutical Co Parche
JP7109093B2 (ja) * 2017-01-31 2022-07-29 帝國製薬株式会社 リドカインおよびジクロフェナクを含む医薬用貼付剤についての投与計画
CN110545796A (zh) * 2017-03-07 2019-12-06 耶路撒冷希伯来大学伊森姆研究发展有限公司 用于活性化合物的局部递送系统
JP7053790B2 (ja) 2018-02-27 2022-04-12 久光製薬株式会社 ジクロフェナク含有乳化ゲル組成物
US20210386858A1 (en) * 2019-02-19 2021-12-16 Bluepharma - Industria Farmacêutica, S.A. Mucoadhesive compositions and uses thereof
JP6744512B1 (ja) * 2020-02-12 2020-08-19 久光製薬株式会社 ジクロフェナクナトリウム含有貼付剤
JP6761553B1 (ja) * 2020-02-12 2020-09-23 久光製薬株式会社 ジクロフェナクナトリウム含有貼付剤
MX2022010593A (es) * 2020-02-27 2022-12-13 Ferring Bv Composiciones tópicas de diclofenaco y métodos.
JP2022096994A (ja) * 2020-12-18 2022-06-30 小林製薬株式会社 外用医薬組成物
US11872320B2 (en) 2021-02-25 2024-01-16 Hisamitsu Pharmaceutical Co., Inc. Method for treating osteoarthritis
IT202100016751A1 (it) 2021-06-25 2022-12-25 Altergon Sa Formulazione topica di diclofenac ad elevato tasso di assorbimento
WO2023052599A1 (en) 2021-10-01 2023-04-06 Nutrition & Biosciences Usa 1, Llc Hydrocolloid blend compositions for topical application
EP4223280A1 (en) * 2022-02-02 2023-08-09 GSK Consumer Healthcare SARL Diclofenac formulations

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
MY148466A (en) 2001-10-26 2013-04-30 Merck Frosst Canada Ltd Granule formulation
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
PE20040321A1 (es) 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US20040096569A1 (en) 2002-11-15 2004-05-20 Barkalow David G. Edible film products and methods of making same
EP1428526A1 (en) 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
CA2538856C (en) * 2003-10-10 2010-06-29 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0524958D0 (en) 2005-12-07 2006-01-18 Pharmakodex Ltd Transdermal administration of active agents
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
TW200815045A (en) 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
EP2055298A1 (en) * 2007-10-30 2009-05-06 Novartis AG Topical composition
US8623401B2 (en) 2008-03-27 2014-01-07 Fenwafe Inc. Wafer formulation
BRPI0921654A2 (pt) * 2008-11-28 2016-02-10 Advance Holdings Ltd formulação farmacêutica
WO2010103845A1 (ja) * 2009-03-11 2010-09-16 興和株式会社 鎮痛・抗炎症剤含有外用剤
BR112012024432A2 (pt) 2010-03-29 2016-05-31 Ferring Bv composição farmacêutica de dissolução rápida
BR112015000329A2 (pt) * 2012-07-12 2017-06-27 Ferring Bv formulações de diclofenac

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019164192A1 (ko) * 2018-02-22 2019-08-29 동아제약 주식회사 비스테로이드성 소염진통 활성성분을 함유하는 필름 형성 약제학적 조성물

Also Published As

Publication number Publication date
EP2872177B1 (en) 2017-12-20
US20180263897A1 (en) 2018-09-20
CA2878784A1 (en) 2014-01-16
EP3275466A1 (en) 2018-01-31
JP6434104B2 (ja) 2018-12-05
JP2015522049A (ja) 2015-08-03
IL236304A0 (en) 2015-02-26
AU2013289403B2 (en) 2017-05-11
JP2018048140A (ja) 2018-03-29
US20150297507A1 (en) 2015-10-22
BR112015000329A2 (pt) 2017-06-27
MX2015000541A (es) 2015-05-11
JP6259454B2 (ja) 2018-01-10
EP2872177A1 (en) 2015-05-20
HK1204973A1 (en) 2015-12-11
CN104428003B (zh) 2020-03-10
US10117829B2 (en) 2018-11-06
NZ702967A (en) 2017-07-28
CN104428003A (zh) 2015-03-18
AU2013289403A1 (en) 2015-01-22
US9999590B2 (en) 2018-06-19
RU2014152445A (ru) 2016-08-27
WO2014009241A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
US10117829B2 (en) Diclofenac formulations
US8470886B2 (en) Topical ibuprofen formulations
CN101790370B (zh) 一种新的双氯芬酸非水局部用溶液及其制备方法
JP7779642B2 (ja) ロキソプロフェン配合皮膚用外用剤
US10322142B2 (en) Polymer matrix compositions comprising a high concentration of bio-fermented sodium hyaluronate and uses thereof
RU2702898C2 (ru) Композиции диклофенака натрия для местного применения
JP2024163305A (ja) ロキソプロフェン及び可溶化剤を含有する皮膚外用剤
US9468618B2 (en) Topical pharmaceutical gel composition of diclofenac sodium
US9687549B2 (en) Topical pharmaceutical gel composition of diclofenac sodium
WO2016137411A1 (en) Topical spray composition comprising ibuprofen and lidocaine
WO2018227044A1 (en) Topical analgesic gel formulations and methods of using them
US20160263065A1 (en) Topical pharmaceutical gel composition of diclofenac sodium
US9468617B2 (en) Topical pharmaceutical gel composition of diclofenac sodium
JP2025020500A (ja) ヘパリン類似物質と第４級アンモニウム基を有する化合物とグリチルリチン酸とを含有する皮膚外用剤
JP2023515539A (ja) 外用ジクロフェナク組成物及び方法
CN104208698A (zh) 一种经皮吸收镇痛消炎药物组合物及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid